ADX-324-302
17 evidence topics · 4 sources
Objective
Registry brief summary
Location and study date
UK research ethics committee opinion
| Field | Reported value |
|---|---|
| REC reference | “26/SC/0102” |
| Date of REC opinion | “12 May 2026” |
| REC opinion | “Further Information Favourable Opinion” |
Study design
Registry design details
| Field | Reported value |
|---|---|
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
Treatment duration and maintenance of the core-study blind
Sponsor description of the extension
Attack recording during the extension
Eligibility criteria
Registry inclusion and exclusion criteria
Eligibility assessment at the end of the core study
Treatment
Regimens by core-study assignment
Registry interventions
| Intervention | Reported description |
|---|---|
| ADX-324 Dose Level 1 | “siRNA duplex oligonucleotide” |
| ADX-324 Dose Level 2 | “siRNA duplex oligonucleotide” |
Study drug cost to participants
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Secondary endpoint: registry definition
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment
Participants analyzed
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No results are available. The extension began in April 2026 and has an estimated primary completion date of June 2030. Allocation is non-randomized and every participant receives onvuzosiran, so the extension has no concurrent control group for safety or attack-rate comparisons. The core-study assignment remains masked through alternating onvuzosiran and placebo injections in the every-6-months group; the extension itself is not blinded to active treatment. Enrollment is limited to participants who completed STOP-HAE, and participants with a negative reaction to study drug in STOP-HAE are excluded, so the extension population may under-represent participants who did not tolerate or did not continue onvuzosiran. The primary endpoint is the incidence and severity of treatment-emergent adverse events through Month 36, and the monthly attack rate is a secondary endpoint. Planned enrollment is approximately 90 participants, which limits the detection of uncommon adverse events. No statistical analysis plan or analysis population definitions have been published.